Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA …
Abstract Around 40–50% of patients with chronic myeloid leukemia (CML) who achieve a
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML)
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for …
D Marin, J Kaeda, R Szydlo, S Saunders, A Fleming… - Leukemia, 2005 - nature.com
We monitored BCR–ABL transcript levels by quantitative real-time PCR in 103 patients
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid …
Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs),
approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and …
approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and …
Discontinuation of imatinib therapy after achieving a molecular response
J Cortes, S O'Brien, H Kantarjian - Blood, 2004 - ashpublications.org
Imatinib has become standard therapy for patients with chronic myelogenous leukemia
(CML). A complete cytogenetic response can be achieved in 75% to 90% of patients treated …
(CML). A complete cytogenetic response can be achieved in 75% to 90% of patients treated …
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and …
S Branford, JF Seymour, A Grigg, C Arthur… - Clinical Cancer …, 2007 - AACR
Purpose: In the first years of imatinib treatment, BCR-ABL remained detectable in all but a
small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL …
small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
DJ Barnes, D Palaiologou, E Panousopoulou… - Cancer research, 2005 - AACR
Chronic myeloid leukemia (CML) starts with the acquisition of a BCR-ABL fusion gene in a
single hematopoietic stem cell, but the time to progression is unpredictable. Although the …
single hematopoietic stem cell, but the time to progression is unpredictable. Although the …
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic …
RD Press, C Galderisi, R Yang, C Rempfer… - Clinical Cancer …, 2007 - AACR
Purpose: Imatinib induces a complete cytogenetic response (CCR) in most chronic myeloid
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …